Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07505771
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Overview
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Sponsor
Unknown Organization
Phase
Early Phase 1
Contacts
Immunome Medical Monitor (CONTACT)
info@immunome.com
425.939.7410
ClinicalTrials.gov
NCT07505771Drug / Compound
IM-3050
Isotope(s):
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- FAP
Ligand Class: Small Molecules
Chelator: DOTA
Eligibility
Inclusion
- Histological or cytological diagnosis of a solid tumor
- During screening, participants must have positive FAP PET/CT uptake as described in criteria for continuation of IM-3050 treatment.
Exclusion
Exclusion criteria not yet provided.
Share your feedback
Help us improve your experience